- Home
- SNGX vs EVAX Comparison
SNGX vs EVAX Comparison
Compare SNGX & EVAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SNGX
- EVAX
- Stock Information
- Founded
- SNGX 1987
- EVAX 2008
- Country
- SNGX United States
- EVAX Denmark
- Employees
- SNGX N/A
- EVAX N/A
- Industry
- SNGX Biotechnology: Pharmaceutical Preparations
- EVAX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- SNGX Health Care
- EVAX Health Care
- Exchange
- SNGX Nasdaq
- EVAX Nasdaq
- Market Cap
- SNGX 7.4M
- EVAX 8.7M
- IPO Year
- SNGX 1987
- EVAX 2021
- Fundamental
- Price
- SNGX $2.32
- EVAX $2.62
- Analyst Decision
- SNGX
- EVAX Strong Buy
- Analyst Count
- SNGX 0
- EVAX 3
- Target Price
- SNGX N/A
- EVAX $33.33
- AVG Volume (30 Days)
- SNGX 620.7K
- EVAX 6.9M
- Earning Date
- SNGX 03-14-2025
- EVAX 03-26-2025
- Dividend Yield
- SNGX N/A
- EVAX N/A
- EPS Growth
- SNGX N/A
- EVAX N/A
- EPS
- SNGX N/A
- EVAX N/A
- Revenue
- SNGX $364,183.00
- EVAX $3,295,000.00
- Revenue This Year
- SNGX N/A
- EVAX $4,845.21
- Revenue Next Year
- SNGX $76.64
- EVAX $30.30
- P/E Ratio
- SNGX N/A
- EVAX N/A
- Revenue Growth
- SNGX N/A
- EVAX N/A
- 52 Week Low
- SNGX $0.32
- EVAX $2.22
- 52 Week High
- SNGX $14.83
- EVAX $23.70
- Technical
- Relative Strength Index (RSI)
- SNGX 36.12
- EVAX 41.09
- Support Level
- SNGX $2.23
- EVAX $2.22
- Resistance Level
- SNGX $2.39
- EVAX $4.05
- Average True Range (ATR)
- SNGX 0.17
- EVAX 1.17
- MACD
- SNGX 0.01
- EVAX 0.00
- Stochastic Oscillator
- SNGX 22.12
- EVAX 6.99
About SNGX Soligenix Inc.
Soligenix Inc is a late-stage biopharmaceutical company based in the United States. It focuses on developing and commercializing products to treat rare diseases where there is an unmet medical need. The company operates through two business segments namely Specialized BioTherapeutics and Public Health Solutions. It generates maximum revenue from Public Health Solutions with active development programs for RiVax, its ricin toxin vaccine candidate, SGX943, its therapeutic candidate for antibiotic resistant and emerging infectious disease, and its research programs to identify and develop novel vaccine candidates targeting viral infection including Ebola, Marburg and SARS-CoV-2 (the cause of COVID-19).
About EVAX Evaxion Biotech
Evaxion Biotech AS is a clinical-stage biotech company that aspires to the exploration of artificial intelligence, or AI, to develop immunotherapies with improved efficacy when compared to currently marketed products for patients with unmet medical needs. Its pipeline programs are derived from its proprietary AI platforms, PIONEER, EDEN, RAVEN, and ObsERV. The company is utilizing these AI platforms to build a drug development pipeline. Its product candidates are; EVX-01 and EVX-02, for the treatment of various cancers, and the third candidate is cancer immunotherapy, EVX-03, for the treatment of various cancers including non-small-cell-lung-cancer, or NSCLC, is in pre-clinical development.